- Status Complete
- Type New application
- Pre-PASC consultation -
- Pre-MSAC consultation -
- Outcome Partially supported
Application details
Reason for application
New MBS item.
Service or technology in this application
Micro-Stent implantation involves a minimally invasive glaucoma surgery (MIGS) device, and is a ab interno, bleb-less, conjunctiva-sparing procedure. The device improves aqueous outflow through the natural physiologic uveoscleral outflow pathway, thereby lowering IOP and dependence on pressure-lowering topical medication. The procedure is generally performed as a day surgery procedure in an ophthalmology surgical setting, in conjunction with cataract surgery or as a stand-alone treatment.
Type: Therapeutic
Medical condition this application addresses
Glaucoma is a chronic degenerative optic neuropathy in which the neuro-retinal rim of the optic nerve becomes progressively thinner, caused by an acquired loss of retinal ganglion cell axons and atrophy of the optic nerve. The lens and cornea of the eye both lack direct blood supply. Therefore, these anterior structures are nourished by a separate circulatory system. The aqueous humour, produced by the ciliary body, circulates throughout the anterior chamber and drains through the uveoscleral outflow in the iridocorneal angle. Its primary role is to maintain intraocular pressure (IOP), and provide nutrients to the structures of the anterior and posterior chambers of the eye. In open-angle glaucoma aqueous outflow is diminished, leading to an elevation of IOP. Patients with glaucoma typically lose peripheral vision, and may suffer complete vision loss if not treated.
Application documents
Application form
PICO confirmation
Public summary document
Public summary document
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Meetings to consider this application
- PASC meeting: 12 April 2017
- ESC meeting: 5 October 2017
- MSAC meeting: 23 November 2017